More than the Eye Can See: Shedding New Light on SARS-CoV‑2 Lateral Flow Device-Based Immunoassays

Containing the global severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has been an unprecedented challenge due to high horizontal transmissivity and asymptomatic carriage rates. Lateral flow device (LFD) immunoassays were introduced in late 2020 to detect SARS-CoV-2 infection in...

Full description

Saved in:
Bibliographic Details
Published in:ACS applied materials & interfaces 2021-06, Vol.13 (22), p.25694-25700
Main Authors: Koller, Garrit, Morrell, Alexander P, Galão, Rui Pedro, Pickering, Suzanne, MacMahon, Eithne, Johnson, Joanna, Ignatyev, Konstantin, Neil, Stuart J. D, Elsharkawy, Sherif, Fleck, Roland, Machado, Pedro Miguel Pereira, Addison, Owen
Format: Article
Language:English
Subjects:
Biological and Medical Applications of Materials and Interfaces
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Containing the global severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has been an unprecedented challenge due to high horizontal transmissivity and asymptomatic carriage rates. Lateral flow device (LFD) immunoassays were introduced in late 2020 to detect SARS-CoV-2 infection in asymptomatic or presymptomatic individuals rapidly. While LFD technologies have been used for over 60 years, their widespread use as a public health tool during a pandemic is unprecedented. By the end of 2020, data from studies into the efficacy of the LFDs emerged and showed these point-of-care devices to have very high specificity (ability to identify true negatives) but inadequate sensitivity with high false-negative rates. The low sensitivity (
ISSN:1944-8244
1944-8252
DOI:10.1021/acsami.1c04283